BR112014027646A2 - método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo - Google Patents
método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduoInfo
- Publication number
- BR112014027646A2 BR112014027646A2 BR112014027646A BR112014027646A BR112014027646A2 BR 112014027646 A2 BR112014027646 A2 BR 112014027646A2 BR 112014027646 A BR112014027646 A BR 112014027646A BR 112014027646 A BR112014027646 A BR 112014027646A BR 112014027646 A2 BR112014027646 A2 BR 112014027646A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- glucuronosyltransferase
- ugt
- udp
- treating
- Prior art date
Links
- 102000016354 Glucuronosyltransferase Human genes 0.000 title abstract 3
- 108010092364 Glucuronosyltransferase Proteins 0.000 title abstract 3
- 230000001413 cellular effect Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 abstract 2
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 abstract 1
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 abstract 1
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 abstract 1
- -1 pterostilbene compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/466,827 US8841350B2 (en) | 2011-05-11 | 2012-05-08 | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| PCT/US2012/064993 WO2013169291A2 (en) | 2012-05-08 | 2012-11-14 | Method for inducing udp-glucuronosyltransferase activity using pterostilbene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014027646A2 true BR112014027646A2 (pt) | 2017-06-27 |
Family
ID=47142275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014027646A BR112014027646A2 (pt) | 2012-05-08 | 2012-11-14 | método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8841350B2 (https=) |
| EP (1) | EP2846785A4 (https=) |
| JP (1) | JP2015523963A (https=) |
| KR (1) | KR20150027081A (https=) |
| CN (1) | CN104768543A (https=) |
| AU (1) | AU2012379655B2 (https=) |
| BR (1) | BR112014027646A2 (https=) |
| CA (1) | CA2872623A1 (https=) |
| IN (1) | IN2014DN09990A (https=) |
| MX (1) | MX2014013503A (https=) |
| WO (1) | WO2013169291A2 (https=) |
| ZA (1) | ZA201408893B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106877A (zh) * | 2014-09-04 | 2017-08-29 | 加利福尼亚大学董事会 | 用于治疗uv诱发的皮肤屏障功能受损的局部用蝶芪组合物 |
| US20160067193A1 (en) * | 2014-09-04 | 2016-03-10 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia |
| JP2018517774A (ja) | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
| US12134956B2 (en) | 2022-10-11 | 2024-11-05 | Halliburton Energy Services, Inc. | Liner hanger system |
| US12398624B2 (en) | 2023-07-11 | 2025-08-26 | Halliburton Energy Services, Inc. | Self-energizing seal for expandable liner hanger |
| US12509957B1 (en) | 2024-09-16 | 2025-12-30 | Halliburton Energy Services, Inc. | Partially bonded seals for well systems |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623724B2 (en) * | 1996-09-18 | 2003-09-23 | Applied Genetics Incorporated Dermatics | Dermatological compositions and methods |
| US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| DE10161253A1 (de) | 2001-12-13 | 2003-06-26 | Dragoco Gerberding Co Ag | Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren |
| FR2869229B1 (fr) | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | Utilisation d'un inducteur des ugt par voie topique |
| ES2246165B1 (es) | 2004-07-20 | 2006-12-01 | Universitat De Valencia | Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer. |
| WO2008070872A1 (en) | 2006-12-07 | 2008-06-12 | Rutgers, The State University Of New Jersey | Prevention and treatment of colon cancer |
| US8509879B2 (en) | 2007-11-06 | 2013-08-13 | The Regents Of The University Of California | Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging |
| WO2009089334A1 (en) * | 2008-01-08 | 2009-07-16 | David Rubin | Method and compositions for preserving wine |
| US20090324740A1 (en) | 2008-06-13 | 2009-12-31 | Albritton Iv Ford D | Novel nasal spray |
| US20100240767A1 (en) | 2009-03-23 | 2010-09-23 | Muhammed Majeed | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof |
| US9737495B2 (en) | 2009-06-22 | 2017-08-22 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
| WO2011042482A1 (en) * | 2009-10-06 | 2011-04-14 | Green Molecular | Polyphenols for use in the treatment of cancer |
| EP2322159A1 (en) | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| US8318807B2 (en) * | 2010-02-03 | 2012-11-27 | Laurus Labs Private Limited | Pterostilbene cocrystals |
| US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
| MX344772B (es) | 2011-01-28 | 2017-01-06 | Univ Kentucky Res Found | Analogos de estilbeno y metodos para tratar cancer. |
| JP6155191B2 (ja) * | 2011-10-02 | 2017-06-28 | キユーピー株式会社 | ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途 |
-
2012
- 2012-05-08 US US13/466,827 patent/US8841350B2/en active Active - Reinstated
- 2012-11-14 WO PCT/US2012/064993 patent/WO2013169291A2/en not_active Ceased
- 2012-11-14 EP EP12876092.3A patent/EP2846785A4/en not_active Withdrawn
- 2012-11-14 KR KR20147034337A patent/KR20150027081A/ko not_active Withdrawn
- 2012-11-14 AU AU2012379655A patent/AU2012379655B2/en not_active Expired - Fee Related
- 2012-11-14 BR BR112014027646A patent/BR112014027646A2/pt not_active IP Right Cessation
- 2012-11-14 CN CN201280074486.2A patent/CN104768543A/zh active Pending
- 2012-11-14 IN IN9990DEN2014 patent/IN2014DN09990A/en unknown
- 2012-11-14 MX MX2014013503A patent/MX2014013503A/es unknown
- 2012-11-14 CA CA2872623A patent/CA2872623A1/en not_active Abandoned
- 2012-11-14 JP JP2015511433A patent/JP2015523963A/ja active Pending
-
2014
- 2014-09-22 US US14/493,058 patent/US10039725B2/en active Active - Reinstated
- 2014-12-04 ZA ZA2014/08893A patent/ZA201408893B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015523963A (ja) | 2015-08-20 |
| KR20150027081A (ko) | 2015-03-11 |
| US8841350B2 (en) | 2014-09-23 |
| IN2014DN09990A (https=) | 2015-08-14 |
| CA2872623A1 (en) | 2013-11-14 |
| US10039725B2 (en) | 2018-08-07 |
| ZA201408893B (en) | 2016-08-31 |
| EP2846785A4 (en) | 2016-06-15 |
| AU2012379655A1 (en) | 2014-11-20 |
| EP2846785A2 (en) | 2015-03-18 |
| WO2013169291A3 (en) | 2015-06-18 |
| AU2012379655B2 (en) | 2018-01-18 |
| MX2014013503A (es) | 2015-11-13 |
| WO2013169291A2 (en) | 2013-11-14 |
| US20150011650A1 (en) | 2015-01-08 |
| US20120289605A1 (en) | 2012-11-15 |
| CN104768543A (zh) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| BR112014027646A2 (pt) | método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| MX2015014512A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| PH12016500443A1 (en) | Modulators of complement factor b | |
| BR112017011900A2 (pt) | tratamento de ataques com fosfatase alcalina recombinante | |
| CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX390159B (es) | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada. | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
| MX377267B (es) | Tratamiento de cáncer con dihidropirazino-pirazinas. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| BR112016007487A2 (pt) | composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica | |
| BR112018006480A2 (pt) | ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula | |
| BR112012008310A2 (pt) | métodos para tratamento de tumores cerebrais | |
| BR112015000616A2 (pt) | tratamento da esclerose múltipla com combinação de laquinimode e fampridina | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2493 DE 16/10/2018. |